Sayda M Elbashir
Overview
Explore the profile of Sayda M Elbashir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1771
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petro C, Hooper A, Peace A, Mohammadi K, Eagan W, Elbashir S, et al.
Sci Transl Med
. 2024 Nov;
16(772):eadn0396.
PMID: 39504352
Increased use of antiviral monoclonal antibodies (mAbs) for treatment and prophylaxis necessitates better understanding of their impact on endogenous immunity to vaccines and viruses. The severe acute respiratory syndrome coronavirus...
2.
Ying B, Liang C, Desai P, Scheaffer S, Elbashir S, Edwards D, et al.
J Virol
. 2024 Aug;
98(9):e0057424.
PMID: 39194250
Boosting with mRNA vaccines encoding variant-matched spike proteins has been implemented to mitigate their reduced efficacy against emerging SARS-CoV-2 variants. Nonetheless, in humans, it remains unclear whether boosting in the...
3.
Desai P, Karl C, Ying B, Liang C, Garcia-Salum T, Santana A, et al.
Sci Transl Med
. 2024 Aug;
16(761):eado1941.
PMID: 39167662
Although vaccines have reduced the burden of COVID-19, their efficacy in helminth infection-endemic areas is not well characterized. We evaluated the impact of infection by (Hpb), a murine intestinal roundworm,...
4.
Liang C, Raju S, Liu Z, Li Y, Arunkumar G, Case J, et al.
Nature
. 2024 May;
630(8018):950-960.
PMID: 38749479
Immune imprinting is a phenomenon in which prior antigenic experiences influence responses to subsequent infection or vaccination. The effects of immune imprinting on serum antibody responses after boosting with variant-matched...
5.
Desai P, Karl C, Ying B, Liang C, Garcia-Salum T, Santana A, et al.
bioRxiv
. 2024 Jan;
PMID: 38293221
Although vaccines have reduced COVID-19 disease burden, their efficacy in helminth infection endemic areas is not well characterized. We evaluated the impact of infection by (Hpb), a murine intestinal hookworm,...
6.
Stewart-Jones G, Elbashir S, Wu K, Lee D, Renzi I, Ying B, et al.
Sci Transl Med
. 2023 Sep;
15(713):eadf4100.
PMID: 37703353
With the success of messenger RNA (mRNA) vaccines against coronavirus disease 2019, strategies can now focus on improving vaccine potency, breadth, and stability. We designed and evaluated domain-based mRNA vaccines...
7.
Narayanan E, Falcone S, Elbashir S, Attarwala H, Hassett K, Seaman M, et al.
Antibodies (Basel)
. 2022 Nov;
11(4).
PMID: 36412833
Monoclonal antibodies have been used successfully as recombinant protein therapy; however, for HIV, multiple broadly neutralizing antibodies may be necessary. We used the mRNA-LNP platform for in vivo co-expression of...
8.
Scheaffer S, Lee D, Whitener B, Ying B, Wu K, Liang C, et al.
Nat Med
. 2022 Oct;
29(1):247-257.
PMID: 36265510
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) vaccine efficacy and persistent transmission. In this...
9.
Scheaffer S, Lee D, Whitener B, Ying B, Wu K, Jani H, et al.
bioRxiv
. 2022 Oct;
PMID: 36263060
The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has resulted in diminished vaccine efficacy and...
10.
Stewart-Jones G, Elbashir S, Wu K, Lee D, Renzi I, Ying B, et al.
bioRxiv
. 2022 Oct;
PMID: 36238717
One Sentence Summary: A domain-based mRNA vaccine, mRNA-1283, is immunogenic and protective against SARS-CoV-2 and emerging variants in mice.